1. Home
  2. SSEA vs TLPH Comparison

SSEA vs TLPH Comparison

Compare SSEA & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSEA
  • TLPH
  • Stock Information
  • Founded
  • SSEA 2024
  • TLPH 2005
  • Country
  • SSEA United States
  • TLPH United States
  • Employees
  • SSEA N/A
  • TLPH N/A
  • Industry
  • SSEA
  • TLPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSEA
  • TLPH Health Care
  • Exchange
  • SSEA Nasdaq
  • TLPH Nasdaq
  • Market Cap
  • SSEA 76.3M
  • TLPH 64.7M
  • IPO Year
  • SSEA 2025
  • TLPH 2011
  • Fundamental
  • Price
  • SSEA $9.99
  • TLPH $1.34
  • Analyst Decision
  • SSEA
  • TLPH Strong Buy
  • Analyst Count
  • SSEA 0
  • TLPH 1
  • Target Price
  • SSEA N/A
  • TLPH $6.00
  • AVG Volume (30 Days)
  • SSEA 45.7K
  • TLPH 318.3K
  • Earning Date
  • SSEA 01-01-0001
  • TLPH 11-12-2025
  • Dividend Yield
  • SSEA N/A
  • TLPH N/A
  • EPS Growth
  • SSEA N/A
  • TLPH N/A
  • EPS
  • SSEA N/A
  • TLPH N/A
  • Revenue
  • SSEA N/A
  • TLPH $28,000.00
  • Revenue This Year
  • SSEA N/A
  • TLPH N/A
  • Revenue Next Year
  • SSEA N/A
  • TLPH $14,533.26
  • P/E Ratio
  • SSEA N/A
  • TLPH N/A
  • Revenue Growth
  • SSEA N/A
  • TLPH N/A
  • 52 Week Low
  • SSEA $9.93
  • TLPH $0.38
  • 52 Week High
  • SSEA $10.00
  • TLPH $1.45
  • Technical
  • Relative Strength Index (RSI)
  • SSEA N/A
  • TLPH 57.82
  • Support Level
  • SSEA N/A
  • TLPH $1.01
  • Resistance Level
  • SSEA N/A
  • TLPH $1.35
  • Average True Range (ATR)
  • SSEA 0.00
  • TLPH 0.11
  • MACD
  • SSEA 0.00
  • TLPH -0.01
  • Stochastic Oscillator
  • SSEA 0.00
  • TLPH 80.49

About SSEA Starry Sea Acquisition Corp Ordinary Shares

Starry Sea Acquisition Corp is a newly organized blank check company.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: